Author

John R. Hawse

Mayo ClinicORCID 0000-0003-3406-470XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Michael J. EmchiD· 2 shared Adam D. BassiD· 1 shared Archit Bajaj· 1 shared August J. JohniD· 1 shared Cristina CorreiaiD· 1 shared Esther P. B. RodmaniD· 1 shared Fatimah J. Al Khazal· 1 shared Gustavo BaldassarreiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Michael J. EmchORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryiSciencePeer-reviewedMay 1, 2026

Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma

Fatimah J. Al Khazal, Michael J. Emch, Cristina Correia…·Louis James Maher III

The paper uses CRISPR screening to identify genetic vulnerabilities in SDH-deficient paraganglioma cells, finding the neddylation pathway as a potential therapeutic target.

DOI 10.1016/j.isci.2026.115885

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

Cancer Biologynpj Precision OncologyPeer-reviewedJul 11, 2025

Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer

Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou…·John R. Hawse

This study identifies lestaurtinib as a potent inhibitor of ovarian cancer, effective against resistant models, by targeting JAK/STAT signaling and synergizing with standard therapies.

8 citations

humanbulk RNA-seq

𝕏 PostBluesky